Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals & M&A

Set Alert for Deals & M&A

BIO: Bayer Operational Model Benefits From Its Arm’s Length Biotechs

There is a lot of structural change going on at the German major but it is learning from the way its wholly owned subsidiaries such as AskBio and BlueRock are run.

Business Strategies Deals

Xencor Gets CD20xCD3 Bispecific Back From J&J

Deal snapshot: J&J decided to return global rights to platotamab, a Phase II-ready CD20xCD3 bispecific antibody for hematological cancers, but remains partnered with Xencor on candidates for prostate cancer and B-cell malignancies.

Deals Business Strategies

AbbVie Adds IBD Candidate In Deal With China’s FutureGen

Deal snapshot: AbbVie joins peers Merck & Co., Roche and Pfizer with a TL1A-targeted antibody for potential therapy in inflammatory bowel disease, paying $150m up front.

Deals Business Strategies

Financial Market At The Start Of An Upswing, For Companies With Focused Strategies

Investors, advisors and companies that have raised cash recently insist funding is available and IPOs are possible for drug developers that can clearly outline future clinical milestones.

BIO Financing

Pfizer And ProFound Partner On Next-Generation Obesity Drugs

Deal Snapshot: Pfizer will collaborate with the Flagship Pioneering-backed startup under a broader long-term partnership between the big pharma and venture capital firm.

Deals Innovation

Stock Watch: Why Have All The Buyouts Gone?

Clinical trial results that readily excite stock market investors are subject to more stringent analysis by big pharma deal-hunters, despite their urgent need for pipeline renewal.

Stock Watch M & A

Deal Watch: Vanda Gets Competing Offer From Cycle After Unsolicited Future Pak Bid

Plus deals involving GSK/Elsie, Lilly/QurAlis, Gilead/Cartography as well as tech transfer announcements and deals in brief.

Deal Watch Business Strategies

GSK Gets RSV Vaccine Expansion To Younger Adults

Arexvy was approved by the US FDA for adults 50-59 with medical conditions that put them at increased risk of severe RSV. Separately, the company ended a cancer deal with SpringWorks.

Approvals Vaccines

Ipsen Dealmaking Heats Up With Marengo Cold Tumor Collaboration

The France-based mid-sized drugmaker has solidified its pipeline through several external pacts in the past few years and its dealmaking is showing no signs of slowing down.

Business Strategies Oncology

Stake Sale Speculation At Two PE-Controlled Firms In India: Will Valuations Fly?

Two top-50 Indian firms are speculated to be on the block with valuations expected to be richer than past multiples paid by buyers. A small, less known life sciences solutions provider is also keen to rope in a CDMO partner. Scrip speaks to a cross-section of experts on the action in deal street.

Commercial M & A

BIO Notebook: Califf On RWE, Industry Execs On Growing Therapeutic Areas, And More

Insights from Day Four of the BIO International Convention include FDA commissioner Califf on the state of real-world evidence and how it impacts IRA negotiations, Roche's interest in cardiovascular/metabolic assets, Merck's plans in immunology, and industry's rising interest in neuropsychiatry. 

BIO Real-World Evidence

BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More

Insights from Day Three of the BIO International Convention in San Diego include Amgen CEO Bob Bradway taking aim at the "Innovation Reduction Act," Novo Nordisk's business development head talking about spending its semaglutide bounty, Roivant's long view on BD prospects for Immunovant's FcRn inhibitor, and more regulatory concerns around artificial intelligence. 

BIO Deals
UsernamePublicRestriction

Register